Fig. 2.

MRIgFUS treatment causes a reduction in Aβ plaque pathology. Plaque load was assessed 4 days following MRIgFUS treatment using immunohistochemistry and stereology. A, Plaques were quantified in MRIgFUS-treated (right) and an equivalent untreated (left) region of the cortex. Significant reductions were observed in mean plaque size (B) and total Aβ surface area (C) in the MRIgFUS-treated compared to untreated cortex. D, Plaque counts within the MRIgFUS-targeted region demonstrated a trend of reduction compared to the untreated region. Within the MRIgFUS-treated cortex, endogenous IgG (F) and IgM (G), were found to be co-localized with plaques (E). At the site of plaques in the untreated cortex (H), a small amount of IgG (I) but no IgM (J) was found. White arrows indicate the location of Aβ plaques (E–J). Scale bar: A=0.5 mm, E–J = 50 μm. Data is presented as paired values between left, untreated and right, MRIgFUS-treated, *p<0.05, **p<0.01.